The "translational gap"
The "translational gap" 1 When a molecular entity is shown to be involved in a given cognitive function, a quasi-2 obligatory conclusion at the end of the paper is highlighting its potential in the therapy of one 3 or the other cognitive disorder. It is a recognized attempt by the authors to connect their work 4 to obvious social benefits and thereby emphasize and enhance the importance of the study.
5
Regretfully, these prophetic statements cannot be taken on face value as "playing a role" in a 6 certain cognitive process may well not mean being a "hot spot" of intervention in defective 7 cognitive functions. These "promising" targets need further validation in order to become 8 suitable subjects of feasible industrial drug development projects.
9
As an example, take two "gold-standard" animal learning assays: scopolamine-induced 10 amnesia in the passive avoidance paradigm and delay-induced forgetting in the novel object 11 recognition task. A PubMed search run for these two methods up to 2015 resulted in 678 hits 12 for the former and 246 hits for the latter. The abstracts were scanned one by one for effective 13 procognitive mechanisms of action identified in the assays. Solely in these two methods 103 14 different modes of action were detected (Table 1) 
19
The large number of potential targets confronts the stark fact that only two types of drugs are 20 in clinical application for dementia and memory impairment: the acetyl-choline-esterase 21 (AchE) inhibitors [1] and an NMDA antagonist, memantine [2] . In some European countries a 22 third class, the so called racetams (piracetam, aniracetam, etc.) with unknown mechanism of 23 action are also in use for mild memory impairments. Unfortunately, the efficacy of currently 24 available medications is, at best, moderate [3, 4] ; the racetams are even not approved in many 25 countries due to lack of clinical evidence. Furthermore, even the "youngest" drug, memantine 26 was launched more than a decade ago (in 2003) ,and the AchE inhibitors already came to 27 market in the nineties, while the appearance of racetams dates back to the 1970s [5] .
28
The increasingly tense unmet need has driven enormous R&D activity in the field, and yet, receptors to a high degree in humans [12, 13] at doses where they produced mild or no effect 28 on cognitive performance in patients [14, 15] .
29
Thus, the major factor responsible for the missing efficacy must have been the 30 inappropriate/invalid modes of action of the compounds. This invalidity is the direct result of 31 insufficient and inappropriate target validation work, both in human and in animal studies, 32 preceding the clinical trials. The former would be even more important than the latter, but it is 1 not the subject of this paper. their internal validity, i.e. how these tests are carried out [16, 17, 18, 19, 20, 21, 72] . Regarding 6 the latter, several shortcomings in methodology corrupting the reliability, reproducibility and 7 robustness of the results have been identified, such as statistically underpowered study design, 8 lack of randomization and blinding, inappropriate (use of) statistics, publication bias, just to 9 name a few. For remediation of the defects in internal validity several guidelines and 10 recommendations have been set forth [17, 19, 22, 23, 24] .
11
The thoroughly analysed internal validity defects, however, do not account for the whole 12 extent of the translational gap. In cognitive enhancer research there are several modes of 13 actions, e.g. muscarinic M1 agonists, histamine H3 antagonists, serotonin 5-HT6 antagonists 14 and nicotinic α7 agonists which have been shown to exert cognitive improving effects on 15 many types of impaired cognitive functions, in several different learning paradigms and with 16 more than a dozen compounds of each type [25, 26, 27, 28] . While a part of the animal studies 17 may be put aside because of methodological deficiencies, the recurrent replication of some potential and all the four underwent extensive clinical investigations [29, 30, 31, 32 ]. Yet, none 22 of them has managed so far to show up a successful Phase III trial on cognitive symptoms.
23
Clearly, there should also be problems with the external validity of the models used. Various 
). These assays gain popularity because they are simple, rapid, and involve elementary 27 cognitive functions well suited for studying fundamental learning and memory processes. By 28 producing lots of valuable data on cognition itself, these assays then became a kind of "gold 29 standard" in the field. Indeed, when considering the massive preclinical evidence for the 30 procognitive efficacy of the above mentioned targets, the reproduced findings are in large part 31 coming from these types of assays [26, 27, 28, 33] cognitive deficit. Therefore, to get a better prediction on the expected human efficacy of a 5 putative enhancer mechanism it should be tested against several impairing methods. By doing 6 so, one can make a virtue of necessity and set up a practically applicable "rule of thumb": the 7 more types of impairing methods against which the studied mechanism is effective the higher 8 the chance it will be effective against the cognitive defects -of otherwise unknown or 9 uncertain origin -in the target disease. results. In addition, such testing procedure would have low clinical relevance, too.
19
To establish a more coherent methodical environment, be suited for the 3R pricinples, and 20 also for mimicking the human clinical circumstances, several cognitive tasks representing 21 different cognitive domains should be taught to the same set of animals, thereby creating a 22 population with "widespread knowledge". This process may take several weeks. These target, i.e. one which satisfactorily fits the desired activity pattern may take quite a long time.
18
By contrast, the above described pattern-based validation offers an alternative way of 19 achieving "the right molecule for the right indication" fit. With this approach, the target 20 disease is not fixed in advance, but is rather determined at the end of the validation process.
21
The potential targets are tested in the full system until a mechanism with appealing efficacy 22 and activity pattern is found. Then the disease whose cognitive deficit pattern best matches 23 the cognitive activity pattern of the selected mechanism should be chosen as the target clinical 24 indication ("science-based selection"). Giving a simplistic example: if a certain mechanism of 25 action shows outstanding efficacy in assays measuring attention then it should be tried in 26 ADHD, whereas if it is more active in social cognition paradigms, then autism could be the 27 preferred choice. In this mechanism-based search for indications no promising target is lost regardless of the disease background. However, establishment of a larger set of models is 31 required which incurs higher running costs and lower testing turnover.
In both cases, a critical methodological factor is how the goodness of pattern-matching is 1 determined/calculated (see Outstanding Questions). Obviously, the better the fit the higher the 2 chance for clinical efficacy, but the exact criteria may be tailored to the needs and 3 expectations of the actual user.
4
The suggested pattern-based validation has analogous logic to that of the "omics" approaches, 5 therefore it may be termed "cognomics" (cognitive omics). According to the author's 6 conviction, it will increase the probability of clinical success compared to the predictive 7 power of the so far applied approach which may be best described as "prove efficacy in the 8 gold standard model then run clinical trials in several disorders". However, adopting the 9 cognomics approach will necessitate the changing of the drug discovery paradigm (see Box   10 2). Disease modifying treatment, which would be the ideal case, relies on our knowledge on the 3 pathomechanism of the disease. The Achilles-heel of any disease modifying approach is the 4 soundness and validity of the underlying hypothesis on the pathomechanism, which can 5 ultimately be checked only in the target patient population.
6
In Alzheimer disease, such a strong theory has been the amyloid cascade hypothesis [54, 56] . testing. However, these animals were much more a model of amyloid intoxication than a 10 model of the disease itself: they lacked tau pathology and the cognitive deficits were 11 discrepant and uncorrelated to the histological changes [57, 58, 59, 60] . Changing the drug discovery paradigm 9
As the pattern-matching approach implies elevated requirements for a certain mechanism or 10 compound for being deemed "efficacious", the number of real hits will foreseeably be However, carrying out all the assays of needed. In humans the term covers a more complex process, including also certain computing 20 activities ("working") with the stored items. 
3
The leftmost column lists assays modelling certain cognitive functions (see Table 1 The leftmost column lists assays modelling certain cognitive functions (see Table 1 ). 
